Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06272864 | BostonGene and Exigent Genomic INsight Study(BEGIN) | recruiting | — | 400 | BostonGeneINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04616209 | Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | recruiting | Phase 1 / Phase 2 | 24 | Precision Biotech Taiwan Corp.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05104515 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | recruiting | Phase 1 | 36 | Oxford Vacmedix UK Ltd.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05257967 | CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease | recruiting | N/A | 10 | British Columbia Cancer AgencyOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06714708 | Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC | recruiting | Phase 2 | 86 | Anhui Provincial Cancer HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04886401 | Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC(PREDICTION) | recruiting | — | 50 | University Hospital, BrestOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06082492 | The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients(NVALT31-PET) | recruiting | N/A | 690 | Radboud University Medical CenterOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06807307 | Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential(KEAPnes) | recruiting | — | 256 | Regina Elena Cancer InstituteOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03740503 | Genomic Investigation of Unusual Responders(GENIUS) | recruiting | — | 100 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05819346 | Digital Lifestyle Intervention for Lung Cancer Survivors(QUALUCA) | recruiting | N/A | 88 | Kai-Uwe Schmitt, PhD, MEng, ICIDOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06630611 | Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)(PragmaTIL) | recruiting | Phase 2 | 40 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT04324164 | Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC | recruiting | — | 800 | Hunan Province Tumor HospitalOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma | recruiting | Phase 1 | 110 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05504278 | Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | recruiting | Phase 1 | 144 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06793813 | Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 44 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06071013 | Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | recruiting | Phase 1 / Phase 2 | 20 | China Medical University HospitalOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06788366 | AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer | recruiting | — | 2,000 | IRCCS San RaffaeleOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06684418 | Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer | recruiting | — | 6,000 | Fudan UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06667167 | First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy | recruiting | Phase 2 | 21 | Nir PeledOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06778512 | LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer | recruiting | — | 2,500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06581419 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 78 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06775275 | A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06467383 | A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced(Key-Early) | recruiting | — | 600 | MSD Italia S.r.l.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT00682032 | The Effect of Beta-glucan in Non-Small Cell Lung Cancer | recruiting | N/A | 300 | University of LouisvilleOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769295 | A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC | recruiting | Phase 2 | 28 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06528743 | Feasibility of Primer Shot Radiotherapy for Non-small Cell Lung Cancer - PRIMER(PRIMER) | recruiting | N/A | 34 | The Netherlands Cancer InstituteOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT06756217 | 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06751849 | Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06751901 | Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment | recruiting | Phase 2 | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752044 | Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment | recruiting | N/A | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752057 | Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment | recruiting | N/A | 10 | The First Affiliated Hospital of Nanchang UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06532591 | Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC | recruiting | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745830 | Lymph Node Pathologic Grading Strategy | recruiting | — | 2,998 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06705465 | Cross-sectorial Rehabilitation of Patients with Lung Cancer | recruiting | N/A | 130 | Camilla BalleOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06737107 | Multicenter Analysis of Different Approaches in Segmentectomies in Early-stage Lung Cancer(ANASEGME) | recruiting | — | 472 | Scientific Institute San RaffaeleOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04170634 | Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study(MEKANOS) | recruiting | — | 220 | Hospices Civils de LyonOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06467617 | Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | recruiting | Phase 2 | 35 | Beijing Chest Hospital, Capital Medical UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06734182 | Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer(neovision) | recruiting | Phase 2 | 25 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06730503 | Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer | recruiting | — | 250 | Shanghai Chest HospitalOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06728852 | Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study(Vigor) | recruiting | Phase 2 | 32 | Li-kun ChenOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06727370 | Cognitive Screening in Lung Cancer Patients | recruiting | — | 200 | European Institute of OncologyOTHER | 1 | Dec 10, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2025source: clinicaltrials